Abbott 2003 Global Citizenship Report - Abbott Laboratories

More documents

Recommendations

Info

Abbott Profile For more than a century, Abbott Laboratories [NYSE: ABT] has been working to help people around the world in their pursuit of healthy lives. We are a broad-based health care company that discovers, develops, manufactures and markets innovative products and services that span the continuum of care – from prevention and diagnosis to treatment and cure. four profile
What We Do Founded in 1888, Abbott’s central purpose is to develop breakthrough health care products that advance patient care for diseases with the greatest unmet medical need. Our principal businesses consist of pharmaceuticals and medical products, including hospital-based medicines and devices, diagnostics tests and instruments, and nutritionals for children and adults. Headquartered in north suburban Chicago, Illinois, United States, Abbott serves customers in more than 130 countries, with a staff of approximately 70,000 employees at more than 135 manufacturing, distribution, research and development, and other facilities around the world. $522 $5,220 $5,685 2003 Net Sales by Division (Dollars in Millions) $2,136 $3,078 $3,040 U.S. Pharmaceuticals U.S. Hospital Products Worldwide Diagnostics U.S. Nutritionals International Other Sales Total Sales: $19,681 $464 $597 $796 $913 $4,255 2003 Net Sales by Country (Dollars in Millions) $11,978 United States Japan Germany Italy Canada Netherlands All Other Countries Total Sales: $19,681 Financial Strength and Stability In 2003, Abbott achieved record sales of $19.7 billion and net earnings of $2.8 billion. In December 2003, Abbott also declared the 320 th consecutive quarterly dividend paid to shareholders since 1924. Our financial performance reflected healthy and sustained growth and returns to our investors. Our balance sheet was strong; our operating cash flow exceeded $3.7 billion in 2003. Complete financial information on Abbott is available at www.abbottinvestor.com. Products Abbott is a market leader in the areas of pharmaceuticals, nutritionals, hospital products and diagnostics. Our products address some of the world’s most prevalent medical conditions, including AIDS, cancer, cardiovascular disease, diabetes, pain management and respiratory infections. Our leading products include the following: Pharmaceuticals • Biaxin/Biaxin XL/Klacid/Klaricid/Klaricid OD (anti-infectives) • Depakote/Depakote ER (neurological treatments) • Flomax (benign prostatic hyperplasia) • Humira (immunology) • Kaletra (protease inhibitor for HIV/AIDS) • Meridia/Reductil (obesity management) • Norvir (protease inhibitor for HIV/AIDS) • Synthroid (thyroid hormone replacement) • TriCor (cholesterol/triglyceride management) Hospital Products • Perclose A-T (vessel closure devices) • Ultane/Sevorane (inhalation anesthetics) • Zemplar (renal disease pharmaceutical) Diagnostics • Abbott Prism (blood screening) • AxSym systems and reagents (immunodiagnostics) • Cell-Dyn (hematology) • LCx (DNA detection) • MediSense products (glucose monitoring) Nutritionals • Ensure/Glucerna (adult nutritionals) • Isomil (soy-based infant formulas) • PediaSure (pediatric nutritionals) • Pedialyte (oral rehydration solution) • Similac (infant formulas) More information about Abbott is available at www.abbott.com. profile five
Page 1 and 2: 2003 Global Citizenship Report Touc
Page 3 and 4: Table of Contents Message From the
Page 5: usinesses serving higher-growth mar
Page 9 and 10: We recognize that citizenship is an
Page 11 and 12: Q&A on Business Ethics Patricia Wer
Page 13 and 14: Update on Ethics and Compliance Lea
Page 15 and 16: Working With Suppliers In 2003, Abb
Page 17 and 18: Q&A on Citizenship in the Supply Ch
Page 19 and 20: Discussion of Key Issues Following
Page 21 and 22: Product Access Programs United Stat
Page 23 and 24: Step Forward Spotlight: Improving A
Page 25 and 26: Global Pharmaceutical Strategy In 2
Page 27 and 28: Intellectual Property Some stakehol
Page 29 and 30: Q&A on Global Diagnostics Research
Page 31 and 32: Diversity and Inclusion in the Work
Page 33 and 34: Diversity programs such as these su
Page 35 and 36: Retirees Our global citizenship str
Page 37 and 38: EHS Policy Abbott’s Environmental
Page 39 and 40: Greenhouse Gas Emissions Abbott ado
Page 41 and 42: EHS Compliance Abbott has a number
Page 43 and 44: Ergonomics Incorporating ergonomics
Page 45 and 46: Q&A on the Commercial EHS Executive
Page 47 and 48: Conservation Highlights of Abbott
Page 49 and 50: Data Summary Table % change Air Emi
Page 52: Please contact us with your questio

Abbott 2003 Global Citizenship Report - Abbott Laboratories

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?